Evidence map›Paper›PMID 21460299›Full record

ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2011

Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia?

Andrea Endimiani, Kristine M Hujer, Andrea M Hujer, Sebastian Kurz, Michael R Jacobs, David S Perlin, Robert A Bonomo

Open access · bronzeAbstract readReview
In one paragraph

Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. The dynamic lung microbiome in health and disease.Nature reviews. Microbiology · 2023
    Review
  8. Article
  9. Urgent need for a rapid microbiological diagnosis in critically ill pneumonia.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022
    Review
  10. Review
  11. Increased Detection of Viruses in Children with Respiratory Tract Infection Using PCR.International journal of environmental research and public health · 2020
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 3 countries.

Andrea EndimianiDepartment of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Kristine M Hujer
Andrea M Hujer
Sebastian Kurz
Michael R Jacobs
David S Perlin
Robert A Bonomo
Louis Stokes Cleveland VA Medical Center · USRutgers, The State University of New Jersey · US

Funding

Understanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6M
Understanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9M
Detecting Carbapenem and Quinolone Resistance in Klebsiella pneumoniae using PCR/R03AI081036 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2009 to 2010
$125k
NIAID NIH HHS R01 AI063517NIAID NIH HHS R01-AI063517NIAID NIH HHS R01 AI072219NIAID NIH HHS R01-AI072219NIAID NIH HHS R03 AI081036NIAID NIH HHS R03-AI081036
6 · The paper itself

Abstract

Hospital-acquired pneumonia represents one of the most difficult treatment challenges in infectious diseases. Many studies suggest that the timely administration of appropriate, pathogen-directed therapy can be lifesaving. Because results of culture and antimicrobial susceptibility testing can take 48 h or longer, physicians currently rely on clinical, epidemiological, and demographic factors to assist with the choice of empiric therapy for antibiotic-resistant pathogens. At present, a number of rapid molecular tests are being developed that identify pathogens and the presence of genetic determinants of antimicrobial resistance (eg, GeneXpert [Cepheid], ResPlex [Qiagen], FilmArray [Idaho Technologies], and Microarray [Check-Points]). In this review, the potential impact that molecular diagnostics has to identify and characterize pathogens that cause hospital-acquired bacterial pneumonia at an early stage is examined. In addition, a perspective on a novel technology, polymerase chain reaction followed by electrospray ionization mass spectrometry, is presented, and its prospective use in the diagnosis of pneumonia is also discussed. The complexities of the pulmonary microbiome represent a novel challenge to clinicians, but many questions still remain even as these technologies improve.

Indexed as

Cross InfectionEarly DiagnosisHumansMolecular Diagnostic TechniquesPneumonia, BacterialPolymerase Chain ReactionSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationTime Factors

Identifiers

PMID21460299
PMCPMC3106236
OpenAlexW2117305364

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.